Abstract 1132
Background
Risk models for NSCLC have identified age as a prognostic factor, but the relevance of molecular biomarkers to age-related outcomes is undefined. We explored the prevalence of biomarkers by age group and the impact of biomarker status on age-related differences in OS among aNSCLC patients (pts) in a real-world population.
Methods
Pts with stage IIIB, IV or recurrent metastatic NSCLC (diagnosed 1/1/11 to 11/30/18) were identified in a US-based, EHR-derived, deidentified database (Flatiron Health). Cox proportional hazard regressions evaluated OS by age at aNSCLC diagnosis (dx) (< vs ≥ 50 years), controlling for gender, histology, race, stage, dx year, smoking status, visit site, region and PDL1 status. Sequential and subgroup regressions modeled ALK+, EGFR+ and ROS1+ biomarker status as mediators of the age effect on OS.
Results
Our sample included 41,024 pts (median age 69 years); median OS was 11 months. Pts <50 years lived longer than pts ≥50 years (HR: 0.83; p < 0.001). Molecular testing and positive results for ALK, EGFR and ROS1 were higher in age <50 (Table); this finding was maintained for non-squamous pts (p ≤ 0.001). Within ALK+, EGFR+ or ROS1+ subgroups, age was not associated with OS. Sequential variable analysis found 35% of the association between age and OS may be explained by ALK, EGFR and ROS1 biomarker status.Table:
1558P Baseline characteristics by age at aNSCLC Dx*
All, n (%) N = 41,024 | < 50 y, n (%) n = 1381 | ≥50 y, n (%) n = 39,643 | |
---|---|---|---|
Female | 19,301 (47) | 716 (52) | 18,585 (47) |
Non-squamous histology | 28,203 (69) | 1092 (79) | 27,111 (68) |
Non-smoker | 4723 (12) | 323 (23) | 4400 (11) |
ALK tested | 23,618 (58) | 948 (69) | 22,670 (57) |
ALK+† | 625 (2.6) | 106 (11) | 519 (2.3) |
EGFR tested | 25,276 (62) | 1000 (72) | 24,276 (61) |
EGFR+† | 3009 (12) | 162 (16) | 2847 (12) |
ROS1 tested | 12,310 (30) | 514 (37) | 11,796 (30) |
ROS1+† | 113 (0.92) | 12 (2.3) | 101 (0.86) |
All age comparisons p < 0.001;
†among tested
Conclusions
Young aNSCLC pts have longer OS than older pts; this benefit is significantly mediated through biomarker status. Pts with mutations had similar OS regardless of age group. As older pts are tested less often and have a lower prevalence of mutations, future work should explore whether increased testing in older pts may mitigate the age-related OS disparity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Flatiron Health.
Funding
Flatiron Health.
Disclosure
A.B. Cohen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Flatiron Health, an independent subsidiary of Roche; Shareholder / Stockholder / Stock options: Roche. B.D.A.P. Neri: Shareholder / Stockholder / Stock options, Full / Part-time employment: Flatiron Health, an independent subsidiary of the Roche group. B.J.S. Adamson: Full / Part-time employment, Provisional patent filed: Flatiron Health, an independent subsidiary of Roche; Non-remunerated activity/ies, Provisional patent filed: University of Washington; Research grant / Funding (self): American Foundation for Pharmaceutical Education; Research grant / Funding (institution): PhRMA Foundation; Leadership role: International Society for Pharmacoeconomics and Outcomes Research; Advisory / Consultancy: Salutis Consulting; Advisory / Consultancy: Fred Hutchinson Cancer Research Center; Advisory / Consultancy: Institute for Disease Modeling, Intellectual Ventures; Advisory / Consultancy: Boston Scientific; Shareholder / Stockholder / Stock options: Roche. C.M. Scanlon: Shareholder / Stockholder / Stock options, Full / Part-time employment: Flatiron Health, an independent subsidiary of Roche. C. Gross: Honoraria (self), Travel / Accommodation / Expenses: Flatiron Health, Inc., which is an independent subsidiary of the Roche Group; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Johnson & Johnson. N.J. Meropol: Shareholder / Stockholder / Stock options, Full / Part-time employment: Flatiron Health, Inc., which is an independent subsidiary of the Roche Group; Shareholder / Stockholder / Stock options: Roche. R.A. Miksad: Shareholder / Stockholder / Stock options, Full / Part-time employment: Flatiron Health, Inc., which is an independent subsidiary of the Roche Group; Shareholder / Stockholder / Stock options: Roche; Advisory / Consultancy: De Luca Foundation.
Resources from the same session
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract
5683 - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Presenter: Naiyarat Prasongsook
Session: Poster Display session 1
Resources:
Abstract